Iron deficiency and anaemia in heart failure: Understanding the FAIR-HF trial

José González-Costello, Josep Comín-Colet

Research output: Contribution to journalReview articleResearchpeer-review

32 Citations (Scopus)


Treatment of anaemia in patients with chronic heart failure (CHF) and reduced left ventricular ejection fraction has traditionally focused on erythropoietin-stimulating agents. However, recent studies have shown that treatment with intravenous (IV) iron can improve the symptoms and quality of life in patients with CHF and iron deficiency (ID), with or without anaemia. The management of ID is becoming an important therapeutic target in patients with CHF, and in this article, we will review iron metabolism in the context of anaemia and heart failure. We will also focus on the importance of diagnosing and treating ID, preferably with IV iron preparations, in patients with CHF. © 2010 The Author.
Original languageEnglish
Pages (from-to)1159-1162
JournalEuropean Journal of Heart Failure
Issue number11
Publication statusPublished - 1 Nov 2010


  • Anaemia
  • Chronic heart failure
  • Iron deficiency
  • Iron therapy


Dive into the research topics of 'Iron deficiency and anaemia in heart failure: Understanding the FAIR-HF trial'. Together they form a unique fingerprint.

Cite this